A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


February 28, 2012

U.K. Guidelines Expand 'Preferred' Treatment Options, Emphasize Treatment as Prevention

Treatment guidelines in the United Kingdom continue to recommend that people living with HIV start antiretroviral (ARV) therapy when the CD4 cell count falls to 350 or below, though the preliminary version released February 4 and reviewed by aidsmap also recommends that health care providers discuss the evidence that treatment reduces the risk of HIV transmission at any CD4 level.  

The new U.K. guidelines also make a clear recommendation on the two nucleoside drugs that should be used as the basis of first-line antiretroviral treatment: Tenofovir and emtricitabine, often used together as Truvada and in other fixed-dose combination tablets. 

“After rigorous review of the published evidence, British doctors have concluded that the U.K. will stick with a CD4 cell count of 350 cells as the threshold for starting treatment in the majority of patients,” the aidsmap report reads. The U.K. guidelines contrast with HIV treatment guidelines in the United States, last updated in October 2011, recommending treatment for all people living with HIV with CD4 counts up to 500 cells. 

For U.K. residents living with HIV who have CD4 cell counts above 350 and want to begin therapy to reduce the risk of transmitting HIV—supported by clinical trials like HPTN 052, demonstrating a 96 percent reduction in the risk of transmitting the virus among HIV-serodiscordant heterosexual couples—the British HIV Association (BHIVA) indicates that these individuals should be allowed to do so. 

The BHIVA guidelines also recommend treatment for certain individuals with CD4s above 350, notably those with AIDS-defining illnesses, HIV-related kidney disease (nephropathy), hepatitis B or hepatitis C coinfection, tuberculosis or non-AIDS cancer requiring immune-suppressive treatment. 

As for what to include in a first-line treatment regimen, tenofovir plus emtricitabine is now the only “preferred” nucleoside reverse transcriptase inhibitor combination for use in combination with a third ARV. Abacavir plus lamivudine, sold in the United Kingdom as Kivexa and the United States as Epzicom, which enjoyed preferred status in the 2008 BHIVA guidelines, is now listed as an “alternative” option, though it should be avoided by those with assumed hypersensitivity to the drug (confirmed via HLA-B*5701 testing), viral loads above 100,000 copies and high cardiovascular disease risk.

Similar to the U.S. treatment guidelines, preferred third drugs in the United Kingdom to be used in combination with tenofovir and emtricitabine include efavirenz—all three ARVs are available as the fixed-dose combination tablet Atripla in the United Kingdom—Isentress (raltegravir), Norvir (ritonavir)-boosted Reyataz (atazanavir) or Norvir-boosted Prezista (darunavir). Previously, aidsmap notes, BHIVA had recommended efavirenz as the only “preferred” option.

Search: United Kingdom, UK, Britain, British HIV Association, BHIVA, guidelines, recommendations, treatment, aidsmap.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.